Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Forms $120 Million Bispecifics Partnership with EpimAb of Shanghai

publication date: Jun 7, 2016
Innovent Biologics of Suzhou announced a $120 million partnership with EpimAb Biotherapeutics, a Shanghai startup with a focus on bispecific antibodies. Innovent will acquire rights to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for China. It will also own the right to out-license the programs to ex-China markets. EpimAb is entitled to an upfront payment and milestones of up to $120 million, royalties and a share of ex-China out-licensings. Innovent said the deal was an addition to the bi-specific antibodies it partnered with Eli Lilly in a $1 billion deal announced in 2015. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital